Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL
2 مناظر
• 07/14/23
0
0
ایمبیڈ
administrator
سبسکرائبرز
In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…
مزید دکھائیں
فیس بک کے تبصرے
SORT BY-
سرفہرست تبصرے
-
تازہ ترین تبصرے